Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marit Ahrens

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|May 6, 2025
Real world comparison of adjuvant vs. salvage radiation therapy on cancer-control outcomes after radical prostatectomyMike Wenzel, Katrin Burdenski, Nikolaos Tselis, et al.
Clinical Genitourinary Cancer|May 30, 2025
Radical Prostatectomy Versus Radiation Therapy for Locally Advanced and Clinically Nodal Positive Prostate CancerMike Wenzel, Katrin Burdenski, Nikolaos Tselis, et al.
Frontiers in Oncology|May 10, 2021
Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination TherapiesMike Wenzel, Felix Preisser, Benedikt Hoeh, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 13, 2021
Initial Clinical Experience with <sup>90</sup>Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 PatientsJustin Ferdinandus, Pedro Fragoso Costa, Lukas Kessler, et al.
Sarcoma|September 21, 2021
Localized Angiosarcoma, Not One Disease: A Retrospective Single-Center Study on Prognosis Depending on the Primary Site and EtiologyInna Schott, Sven-Thorsten Liffers, Farhad Farzaliyev, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2022
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer EntitiesWolfgang P Fendler, Kim M Pabst, Lukas Kessler, et al.
European Journal of Cancer Care|August 3, 2021
Quality of life of GIST patients with and without current tyrosine kinase inhibitor treatment: Cross-sectional results of a German multicentre observational study (PROSa)Martin Eichler, Daniel Pink, Franka Menge, et al.
International Journal of Cancer|November 29, 2025
Real-world efficacy and toxicity of ipilimumab and nivolumab as a first-line treatment for advanced renal cell carcinoma according to IMDC risk criteria-A multi-center retrospective analysis on behalf of the GUARDIANS groupHendrik Dinkel, Linus Materna, Ramona Stelmach, et al.
Cancers|December 3, 2020
The Health-Related Quality of Life of Sarcoma Patients and Survivors in Germany-Cross-Sectional Results of a Nationwide Observational Study (PROSa)Martin Eichler, Leopold Hentschel, Stephan Richter, et al.
European Journal of Cancer (Oxford, England : 1990)|June 3, 2026
Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological reviewMarit Ahrens, John Haanen, Laurence Albiges, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Strahlentherapie Und Onkologie : Organ Der Deutschen Rontgengesellschaft ... [Et Al]|May 6, 2025
Real world comparison of adjuvant vs. salvage radiation therapy on cancer-control outcomes after radical prostatectomyMike Wenzel, Katrin Burdenski, Nikolaos Tselis, et al.
Clinical Genitourinary Cancer|May 30, 2025
Radical Prostatectomy Versus Radiation Therapy for Locally Advanced and Clinically Nodal Positive Prostate CancerMike Wenzel, Katrin Burdenski, Nikolaos Tselis, et al.
Frontiers in Oncology|May 10, 2021
Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination TherapiesMike Wenzel, Felix Preisser, Benedikt Hoeh, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 13, 2021
Initial Clinical Experience with <sup>90</sup>Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 PatientsJustin Ferdinandus, Pedro Fragoso Costa, Lukas Kessler, et al.
Sarcoma|September 21, 2021
Localized Angiosarcoma, Not One Disease: A Retrospective Single-Center Study on Prognosis Depending on the Primary Site and EtiologyInna Schott, Sven-Thorsten Liffers, Farhad Farzaliyev, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2022
Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer EntitiesWolfgang P Fendler, Kim M Pabst, Lukas Kessler, et al.
European Journal of Cancer Care|August 3, 2021
Quality of life of GIST patients with and without current tyrosine kinase inhibitor treatment: Cross-sectional results of a German multicentre observational study (PROSa)Martin Eichler, Daniel Pink, Franka Menge, et al.
International Journal of Cancer|November 29, 2025
Real-world efficacy and toxicity of ipilimumab and nivolumab as a first-line treatment for advanced renal cell carcinoma according to IMDC risk criteria-A multi-center retrospective analysis on behalf of the GUARDIANS groupHendrik Dinkel, Linus Materna, Ramona Stelmach, et al.
Cancers|December 3, 2020
The Health-Related Quality of Life of Sarcoma Patients and Survivors in Germany-Cross-Sectional Results of a Nationwide Observational Study (PROSa)Martin Eichler, Leopold Hentschel, Stephan Richter, et al.
European Journal of Cancer (Oxford, England : 1990)|June 3, 2026
Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological reviewMarit Ahrens, John Haanen, Laurence Albiges, et al.
Pageof 3